Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Greg Jung who wrote (82)	9/27/1999 8:57:00 AM
From: Steve Push	Read Replies (1) \| Respond to of 360

Greg, One potential application of the Flow-thru Chip(TM) microarray would be screening new drug leads. In this application, probes representing one or more drug targets would be attached to the channels. A cell or tissue culture would be treated with the drug lead, and the chip would be used to measure the abundance in the cells or tissues of the mRNA species corresponding to the drug target(s). We would be looking for changes in the expression profile away from the characteristic disease pattern and toward the characteristic normal pattern. This message contains forward-looking statements about development of the Flow-thru Chip. Such statements reflect management's current view of future events. Actual results may differ materially from these projections because of a number of factors, including risks related to technological challenges, technological advances, and demand for the Flow-thru Chip. There is no assurance that Gene Logic will be able to commercialize the Flow-thru Chip. These risk factors and others are more fully described in the company's Annual Report on Form 10-K for the year ended December 31, 1998, and other documents filed with the Securities and Exchange Commission. Steve Push Vice President, Corporate Communications Gene Logic Inc. Note: I participate occasionally on this message board as an official company spokesperson. Because of time constraints, however, I cannot respond to all questions. My failure to comment on or respond to someone else's message implies neither agreement nor disagreement with the information in that message. Past messages that I have posted may now contain out-of-date information. To be certain that you have the latest information about Gene Logic, please read recent press releases, SEC filings, and other documents available on our Web site (http://www.genelogic.com).